PI-103

PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

価格 在庫  
USD 168 あり
USD 185 あり
USD 340 あり
USD 466 あり

PI-103 化学構造
分子量: 348.36

高品質保証

カスタマーフィードバック(4)

Quality Control & MSDS

製品説明

  • Compare PI3K Inhibitors
    PI3K製品生物活性の比較
  • 研究分野
  • PI-103のメカニズム

製品の説明

生物活性

製品説明 PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。
ターゲット p110α p110β p110δ p110γ mTOR DNA-PK
IC50 2 nM 3 nM 3 nM 15 nM 30 nM 23 nM [3]
In vitro試験 PI-103 potently inhibits both the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. [1] PI-103 inhibits constitutive and growth factor-induced PI3K/Akt, as well as mTORC1 activation. [2] In blast cells, PI-103 inhibits leukemic proliferation, the clonogenicity of leukemic progenitors and induces mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 inhibits p110α >200-fold more potently than p110β. PI-103 also potently blocks production of PI(3,4)P2 and PIP3 in adipocytes and PIP3 in myotubes. [2] PI-103 inhibits phosphorylation of Akt with an IC95 100-fold lower than that for LY294002. Strikingly, PI-103 completely protects animals from insulin-stimulated decline in blood glucose. PI-103 has additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [2]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SK-N-BE MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOwMVgh|ryP MWGyOE81QC95MjDo NHfjNVBqdmS3Y3XzJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDpcohq[mm2aX;uJI9vKE6EIHPlcIwh\3Kxd4To M4DqVFI3OjJ2Nkix
SH-SY5Y NF3SbplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHFTW8xNThizszN NWrhNXlKOjRxNEivO|IhcA>? NXrT[WpMcW6mdXPld{B1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgbY5pcWKrdHnvckBwdiCQQjDj[YxtKGe{b4f0bC=> Mlu0NlYzOjR4OEG=
SH-SY5Y  NX\Fd5diSXCxcITvd4l{KEG|c3H5 NV23W281OSEQvF2= MYmwMlUuOjRiaB?= M2XYNpNmdnOrdHn6[ZMhdmW3cn;icIF{fG:vYTDj[YxteyC2bzDkc5hwenWkaXPpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NHOzbVAzPjJ{NE[4NS=>
G 35 SC NVe4eJp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj5NE4xPS1{MDFOwG0> NW\6cGtZOjRxN{KgbC=> M4D6PGROW09? M4HKeolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? M1;KU|I3OTJzMkWx
G 38 SC M3;HPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSwMlA2NTJyIN88US=> MVGyOE84OiCq NFviU4RFVVOR MVnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 Mn;CNlYyOjF{NUG=
G 40 SC M3LrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHn5V5UxNjB3LUKwJO69VQ>? NW\aT3FNOjRxN{KgbC=> NHnH[oNFVVOR MWrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueIx6 M3vGdlI3OTJzMkWx
G 35 DC NHe5eplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\XOlAvODVvMkCg{txO NWSzb45EOjRxN{KgbC=> MknkSG1UVw>? M1vtPYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? NWi5PXVPOjZzMkGyOVE>
G 38 DC NV:3dpdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVuwXJFqOC5yNT2yNEDPxE1? NHzZcGozPC95MjDo M4rKN2ROW09? Ml:2bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBidmRidHnt[UBl\XCnbnTlcpRtgQ>? NXPMRol2OjZzMkGyOVE>
G 40 DC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q4XVAvODVvMkCg{txO MnPPNlQwPzJiaB?= MYfEUXNQ NIjLNVdqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfGy7 MnqzNlYyOjF{NUG=
RD MlP4RZBweHSxc3nzJGF{e2G7 NVr2UWM{OS9zLkWvNkDPxE1? M4jjd|czKGh? M2XPc4lv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiR1HOWFYy NYWxe3FjOjV5NEmzO|g>
TE381.T MoXqRZBweHSxc3nzJGF{e2G7 M4\JS|EwOS53L{Kg{txO MV:3NkBp MnTsbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> MVSyOVc1QTN5OB?=
RMS13 NWPPZ|VLSXCxcITvd4l{KEG|c3H5 M1;TS|EwOS53L{Kg{txO NGXZVWk4OiCq Mn;pbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> M4DYOFI2PzR7M{e4
RH30  NU\SZlhxSXCxcITvd4l{KEG|c3H5 NXm3PYJoOS9zLkWvNkDPxE1? NUfUcZFPPzJiaB?= MVrpcoR2[2W|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKEeDTmS2NS=> MnzUNlU4PDl|N{i=
VJ M3fjU2Fxd3C2b4Ppd{BCe3OjeR?= M2XGPFEwOS53L{Kg{txO NGL6fWs4OiCq MoKxbY5lfWOnczDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCJQV7UOlE> M3vpXlI2PzR7M{e4
HS578T MVLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MofrNE0{KM7:TR?= MXG3NkBp NHzX[llqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NHfPS2gzPTd{MUSxPS=>
BT549 NYK0UW5xS2WubDDWbYFjcWyrdImgRZN{[Xl? NHzkUHMxNTNizszN NVjPfJdqPzJiaB?= NHnzb3hqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NWjmOZpDOjV5MkG0NVk>
MDA-MB-231 NWjHVllFS2WubDDWbYFjcWyrdImgRZN{[Xl? NVvWcYtsOC1|IN88US=> MljDO|IhcA>? M2nCRolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M3yxeFI2PzJzNEG5
MDA-MB-468 NX3IRmp1S2WubDDWbYFjcWyrdImgRZN{[Xl? NGPkeJIxNTNizszN MUO3NkBp NVvP[WlrcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= MoexNlU4OjF2MUm=
MDA-MB-436 NYLKNFg{S2WubDDWbYFjcWyrdImgRZN{[Xl? MV[wMVMh|ryP Mmn2O|IhcA>? M13qUolvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NHzUU3AzPTd{MUSxPS=>
SUM149PT NFTCRWdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3HDelAuOyEQvF2= MXK3NkBp M2W1OIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M3rINVI2PzJzNEG5
MDA-MB-468 M4PYRWZ2dmO2aX;uJGF{e2G7 MXWwMlAyNTFyIN88US=> M2npd|I1KGh? M1W3NYRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? MkflNlU4OjF2MUm=
MDA-MB-231 NXrZSpFJTnWwY4Tpc44hSXO|YYm= MlHHNE4xOS1zMDFOwG0> NGLYbJUzPCCq NYD6T|U2\G:5boLl[5Vt[XSnczD0bIUhdGW4ZXzzJI9nKM7{LWTyR3AyNCClLV35Z{BidmRiY4njcIlvKEVicILveIVqdnQEoB?= NHfRdYMzPTd{MUSxPS=>
HS578T NFrHdGZHfW6ldHnvckBCe3OjeR?= MnPYNE4xOS1zMDFOwG0> NXLHSoZuOjRiaB?= M4\mXoRwf26{ZXf1cIF1\XNidHjlJIxmfmWuczDv[kDPui2WclPQNUwh[y2PeXOgZY5lKGO7Y3zpckBGKHC{b4TlbY5{yqB? NH\ScpYzPTd{MUSxPS=>
SW872 NY\lcnhWTnWwY4Tpc44hSXO|YYm= NF72blAxNjBzLUCuOUDPxE1? MXqyOEBp NV3hblU{emWmdXPld{BCU1RicHjvd5Bpd3K7bHH0bY9vKCiyQVvULUBidmRiNFXCVFEheGixc4Doc5J6dGG2aX;uJEhxPEWEUEGpJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA> M1exUFI1Pjl3NkOy
SW982 M4nYdGZ2dmO2aX;uJGF{e2G7 MnmzNE4xOS1yLkWg{txO MXGyOEBp MXvy[YR2[2W|IFHLWEBxcG:|cHjvdplt[XSrb36gLJBCU1RrIHHu[EA1TUKSMTDwbI9{eGixconsZZRqd25iKIC0SWJROSliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= NGT6ZmUzPDZ7NU[zNi=>
SW872 MkWyRZBweHSxc3nzJGF{e2G7 NFLlcm8xNjBzLUCuOUDPxE1? M4HPV|Q5KGh? Mk[4bY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M4D2Z|I1Pjl3NkOy
SW982 NFfzbYZCeG:ydH;zbZMhSXO|YYm= NFjMXHgxNjBzLUCuOUDPxE1? M2q1NlQ5KGh? M1L4NYlv\HWlZYOgZZBweHSxc3nzJIRwe2ViZHXw[Y5l\W62bIm= M3PWV|I1Pjl3NkOy
AGS HG NXu1SGFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwNkigxtEhOC5yM{Gg{txO NIXoSVAzPDV7N{S3PC=>
AGS LG MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:0PWlEPTB;MD6wOUDDuSByLkCwNUDPxE1? MVeyOFU6PzR5OB?=
HGC27 HG M1foemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e0U2lEPTB;MD6zPEDDuSByLkCyNkDPxE1? MUSyOFU6PzR5OB?=
HGC27 LG Mnn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHjTWM2OD1yLkCyJOKyKDBwMEC0JO69VQ>? M1jEOlI1PTl5NEe4
MKN45 HG MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3n2RmlEPTB;MT6wNUDDuSByLkC1NUDPxE1? MYqyOFU6PzR5OB?=
MKN45 LG MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwOEegxtEhOC5yM{Cg{txO M4jVelI1PTl5NEe4
NUGC4 HG MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF2LkCgxtEhOy57MUOg{txO M4PvflI1PTl5NEe4
NUGC4 LG M3jGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3UTWM2OD1zND6wJOKyKDVwM{KxJO69VQ>? NHTmVJkzPDV7N{S3PC=>
A549 NUDVbm1{TnWwY4Tpc44hSXO|YYm= MX2wMlI2NzBwNT:xJO69VQ>? NEmxWoYzPCCq M4XhS4lvcGmkaYTzJGFsfCCyaH;zdIhwenmuYYTpc44he2yrZ3j0cJk> M2jy[|I1OzVzNEK1
H460 MnL4SpVv[3Srb36gRZN{[Xl? M4LvTVAvOjVxMD61M|Eh|ryP NUe5Rml4OjRiaB?= MortbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{dGmpaITsfS=> M{XzVFI1OzVzNEK1
H661 MUXGeY5kfGmxbjDBd5NigQ>? MXKwMlI2NzBwNT:xJO69VQ>? NXzNWYo1OjRiaB?= MVHpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? MU[yOFM2OTR{NR?=
SAS M2KwOWZ2dmO2aX;uJGF{e2G7 NH35dVcxNjJ3L{CuOU8yKM7:TR?= MoPXNlQhcA>? MWLpcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? MmfFNlQ{PTF2MkW=
UT5 MlPRSpVv[3Srb36gRZN{[Xl? MV[wMlI2NzBwNT:xJO69VQ>? NVmxfJVxOjRiaB?= MW\pcohq[mm2czDBb5QheGixc4Doc5J6dGG2aX;uJJNq\26rZnnjZY51dHl? MXmyOFM2OTR{NR?=
FaDu NG\kR3ZHfW6ldHnvckBCe3OjeR?= MYGwMlI2NzBwNT:xJO69VQ>? MYSyOEBp MmjvbY5pcWKrdIOgRYt1KHCqb4PwbI9zgWyjdHnvckB{cWewaX\pZ4FvfGy7 MoTtNlQ{PTF2MkW=
RD MlrKRZBweHSxc3nzJGF{e2G7 M1P0cFEwOS53L{Kg{txO NV;6SmtuPzJiaB?= M4TZNGROW09? NVz0OmtbcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? MkXDNlM3QDR7MkW=
TE671 M{HCS2Fxd3C2b4Ppd{BCe3OjeR?= NIrlfHQyNzFwNT:yJO69VQ>? NULycmlZPzJiaB?= NX\rR|VyTE2VTx?= MWHpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKFWRMUK2 NVzQfFI{OjN4OES5NlU>
RH30  NFW0NFdCeG:ydH;zbZMhSXO|YYm= NGnpOZkyNzFwNT:yJO69VQ>? MYq3NkBp NWrSNYFsTE2VTx?= NXfTVWJ3cW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDVU|EzPg>? MYKyN|Y5PDl{NR?=
RMS13 NEXvNoNCeG:ydH;zbZMhSXO|YYm= MmTWNU8yNjVxMjFOwG0> NUnJW5lJPzJiaB?= MXPEUXNQ MmCwbY5lfWOnczDjZZNx[XOnLXTldIVv\GWwdDDhdI9xfG:|aYOgZ49u[mmwZXSge4l1cCCXT{GyOi=> MoeyNlM3QDR7MkW=
SUM149PT MmrwR4VtdCCYaXHibYxqfHliQYPzZZk> MV2wMlMh|ryP M4r0WFczKGh? NIDROo5mdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? MUmyN|YxOTB5NB?=
MDA-MB-468 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGDuRm8xNjNizszN M4HrfFczKGh? NIfJcVZmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? NHvYVoczOzZyMUC3OC=>
MDA-MB-231 MV3D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NY[5TY9VOC5|IN88US=> M3HTOFczKGh? NIjUZpJmdmijbnPld{BkgXSxdH;4bYMh\W[oZXP0d{Bw\iCSSUPLM2FMXCCyYYToe4F6KGmwaHnibZRwenN? M2XLclI{PjBzMEe0
SY5Y NEHNWnhHfW6ldHnvckBCe3OjeR?= MYWxMlUwOi53L{Wg{txO M3XLdVI1KGh? NHrneGhqdmS3Y3XzJGcyyqClZXzsMYN6[2ynIHHydoV{fCCjbnSgZZBweHSxc3nz NFXPZ4szOzN5OEO0NS=>
SKNBE(2c) NITTcWJHfW6ldHnvckBCe3OjeR?= NVmyO41pOS53L{KuOU82KM7:TR?= M{TObVI1KGh? M3PweYlv\HWlZYOgS|HDqGOnbHytZ5lkdGViYYLy[ZN1KGGwZDDhdI9xfG:|aYO= MVSyN|M4QDN2MR?=
RD MX7BdI9xfG:|aYOgRZN{[Xl? NYTNZoR{OyEEtV2= NI\Y[ZUyOiCq M3jmOWROW09? NH\WPFR{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MWCyN|MxODhyOR?=
TP5014 NFzSUpdCeG:ydH;zbZMhSXO|YYm= NVPrdXBvOyEEtV2= MUGxNkBp NEXDOnlFVVOR NHnqSYt{\W6|aYTpfoV{KFKGIHPlcIx{KHSxIFTPXE1qdmS3Y3XkJIFxd3C2b4Ppdy=> MX6yN|MxODhyOR?=
HT1080 NV:3e4x{SXCxcITvd4l{KEG|c3H5 MlrpN{DDvU1? NHq4NncyOiCq NVvLSXU4TE2VTx?= MkPCd4Vve2m2aYrld{BTTCClZXzsd{B1dyCGT2itbY5lfWOnZDDhdI9xfG:|aYO= MojDNlM{ODB6MEm=
A549 MYfGeY5kfGmxbjDBd5NigQ>? NUPWelFUOC1|LkOg{txO MlXpO|IhcA>? NHPTOHZqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? M3rwVFI{OjV7NUmx
HCC827 NGTDTphHfW6ldHnvckBCe3OjeR?= MmrvNE0{NjNizszN NHHF[pU4OiCq NGPw[3RqdmS3Y3XzJINwdXCuZYTlJIRwf26{ZXf1cIF1cW:wIH;mJJBCU1R? MV:yN|I2QTV7MR?=
H3122 NHHUcIhHfW6ldHnvckBCe3OjeR?= MorqNE0{NjNizszN NVHLTHlmPzJiaB?= M2GyeYlv\HWlZYOgZ49ueGyndHWg[I94dnKnZ4XsZZRqd25ib3[gdGFMXA>? MmX3NlMzPTl3OUG=
TALL-1 NUjDcldUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r5[|HjiIoQvF2= M37tNlch\A>? MWDk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NVfndYxmOjNyM{iyO|M>
HPB-ALL NYn3W5puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHGNgKBkc7:TR?= MnnJO{Bl NXj0TXJu\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 NEjle40zOzB|OEK3Ny=>
DND41 M3XyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfZcFMy6oDLzszN MVG3JIQ> NFTBVGVl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NEXONoszOzB|OEK3Ny=>
SUP-T1 M1ThOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\WWJhjOeLCid88US=> NETxVXQ4KGR? MUjk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> NEP5fYQzOzB|OEK3Ny=>
PEER Mny1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXDeW9XOeLCid88US=> NV7i[294PyCm MUDk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> MW[yN|A{QDJ5Mx?=
ALL-SIL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYex5qCK|ryP MknUO{Bl NUTwZlZD\GWlcnXhd4V{KHSqZTDj[YxtKG63bXLldkB{cWewaX\pZ4FvfGy7 MmWyNlMxOzh{N{O=
KE37 M1;Ydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzQNgKBkc7:TR?= MkP1O{Bl NIjpXoxl\WO{ZXHz[ZMhfGinIHPlcIwhdnWvYnXyJJNq\26rZnnjZY51dHl? NHSzenozOzB|OEK3Ny=>
Karpas-45 Ml;FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\IdlHjiIoQvF2= NIr6emE4KGR? MWXk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> Mnf3NlMxOzh{N{O=
RPMI-8402 NUHLVZZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX36R2pROeLCid88US=> MkPUO{Bl M{f5[oRm[3KnYYPld{B1cGViY3XscEBvfW2kZYKgd4lodmmoaXPhcpRtgQ>? MW[yN|A{QDJ5Mx?=
Jurkat MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGq4bnEy6oDLzszN NHewVGE4KGR? MYnk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> M3zjSlI{ODN6Mkez
MOLT-4 M{jwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUT2Xmd7OeLCid88US=> NH;LS2Q4KGR? MkDq[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 M3qyTVI{ODN6Mkez
PF-382 NYLjSZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjVZ|My6oDLzszN M3nIbVch\A>? MVPk[YNz\WG|ZYOgeIhmKGOnbHygcpVu[mW{IIPp[45q\mmlYX70cJk> Ml;1NlMxOzh{N{O=
CCRF-CEM MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:0[VHjiIoQvF2= NGDEW2U4KGR? MmXC[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 MWGyN|A{QDJ5Mx?=
LOUCY NU[wb4drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rLNFHjiIoQvF2= MUi3JIQ> MnfW[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NXXQTWJqOjNyM{iyO|M>
MOLT-16 NF3pN5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DGT|HjiIoQvF2= M{DqV|ch\A>? MoLu[IVkemWjc3XzJJRp\SClZXzsJI52dWKncjDzbYdvcW[rY3HueIx6 NWfDNFc1OjNyM{iyO|M>
MM1S M1nzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXYNE0zKM7:TR?= MVWyOEBp MofHTWM2OD1yLkWg{txO NI[4[mwzOjh{OUKzOC=>
NCI-H929 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TvTVAuOiEQvF2= M3vYflI1KGh? MX7JR|UxRTBwMkWg{txO NEXwW|AzOjh{OUKzOC=>
KMS12-BM  MnXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED1UGUxNTJizszN MXmyOEBp NXP5VIR7UUN3MP-8olIh|ryP M{HhflIzQDJ7MkO0
MDA-MB-436 Mn7XSpVv[3Srb36gRZN{[Xl? NX\Tb4VZOSEQvF2= M2O4e|I1KGh? MnHSdoVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MlLqNlI1QDh3OUC=
SUM149PT MVzGeY5kfGmxbjDBd5NigQ>? M2LJXFEh|ryP NITCVlQzPCCq MUXy[YR2[2W|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW MV6yNlQ5QDV7MB?=
SUM1315MO2 MWDGeY5kfGmxbjDBd5NigQ>? NFzEc4gyKM7:TR?= MkPuNlQhcA>? NGrJZ4Jz\WS3Y3XzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiQVvU MnTmNlI1QDh3OUC=
HCC1937 NVTGSXl3TnWwY4Tpc44hSXO|YYm= MnjHNUDPxE1? Mm[0NlQhcA>? Mlj5doVlfWOnczD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= MVGyNlQ5QDV7MB?=
HCC827 M4fIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWewMVMh|ryP MlXzO|IhcA>? NWrSZmJ2UUN3ME2wMlMh|ryP NVLPWZB1OjF{MkC0O|Q>
PC-9  NWrBfJMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;4N|AuOyEQvF2= NYP1NpFuPzJiaB?= NX\W[WF2UUN3ME2wMlgh|ryP M1nwdlIyOjJyNEe0
LN229 MVrGeY5kfGmxbjDBd5NigQ>? NHryfG4yKM7:TR?= NGfwR4s1QCCq MXXpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v MoS2NlExPjJ7OUO=
U87 NH3Z[XVHfW6ldHnvckBCe3OjeR?= MkjGNUDPxE1? MVe0PEBp MY\pcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v MmrqNlExPjJ7OUO=
U373 MW\GeY5kfGmxbjDBd5NigQ>? M4LoflEh|ryP MW[0PEBp MVXpcoR2[2W|IHH1eI9xcGGpb4PvcYUh\m:{bXH0bY9v Ml76NlExPjJ7OUO=
SF767 Mme4SpVv[3Srb36gRZN{[Xl? NFviXZYyKM7:TR?= M170TlQ5KGh? NGfLTXNqdmS3Y3XzJIF2fG:yaHHnc5NwdWViZn;ycYF1cW:w NFLq[2EzOTB4Mkm5Ny=>
Mel-Juso Mnr6R4VtdCCYaXHibYxqfHliQYPzZZk> M3fEPFAvODIkgKOxNQKBkc7:TR?= NV3DdXRHPzJiaB?= MYLpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NYPPe4d7OjFyNEi3PFU>
518A2  NF3qe3FE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXX3[5hROC5yMfMAl|Ex6oDLzszN Ml;BO|IhcA>? MnfjbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NETDVG4zOTB2OEe4OS=>
Mel-Juso  NEnrRmRHfW6ldHnvckBCe3OjeR?= M1;oWVAvODBz4pETNgKBkc7:TR?= M1PvWFI1KGh? M4HVOpN2eHC{ZYPz[ZMheGixc4Doc5J6dGG2aX;uJI9nKHCqb4PwbIF1cWS7bDDpco9{cXSxbDCzMYtqdmG|ZTDkc5dve3S{ZXHtJJRiemendIO= MoXCNlExPDh5OEW=
518A2 NUizV4NDTnWwY4Tpc44hSXO|YYm= NGrxOGYxNjByMfMAl|HjiIoQvF2= MlXrNlQhcA>? NEj3c41{fXCycnXzd4V{KHCqb4PwbI9zgWyjdHnvckBw\iCyaH;zdIhifGmmeXygbY5we2m2b3ygN{1scW6jc3Wg[I94dnO2cnXhcUB1[XKpZYTz MnLINlExPDh5OEW=
PC3  NWr3d3hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHzNZYzPGh? MVLHTVUxyqB;IEGwNEBvVQ>? NGntSGszODV3MUC2NS=>
U87MG NU\VfY43TnWwY4Tpc44hSXO|YYm= MoDYNE4yNTFizszN M4G5c|I16oDLaNMg NIf1dHFFVVOR MoixbY5pcWKrdIOgVGk{Uy2vZXTpZZRm\CC|aXfuZYxqdmd? MXmxPVY{OzZ6Mx?=
U138MG MoHMSpVv[3Srb36gRZN{[Xl? M2ryOVAvOS1zIN88US=> NV\wW2xyOjUkgJnoxsA> M{P6VWROW09? NIW1SoVqdmirYnn0d{BRUTONLX3l[IlifGWmIIPp[45idGmwZx?= MX2xPVY{OzZ6Mx?=
U118MG MoP1SpVv[3Srb36gRZN{[Xl? Mn;iNE4yNTFizszN NHL6ZY0zPOLCiXlCpC=> NGHRWIRFVVOR M1TFeolvcGmkaYTzJHBKO0tvbXXkbYF1\WRic3nncoFtcW6p Mmq1NVk3OzN4OEO=
U87MG MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTibmZKSzVyPUCuNVQh|ryP M2TuOVE6PTh2MkK3
IGROV-1 Ml7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwME[g{txO MkizNVk2QDR{Mke=
DETROIT562 NFTO[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwMUOg{txO MnjZNVk2QDR{Mke=
PC3  MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTBwMUCg{txO NVu3XoVpOTl3OESyNlc>
SKOV-3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHWyb5dKSzVyPUCuNVIh|ryP MVOxPVU5PDJ{Nx?=
HUVEC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrUeZFKSzVyPUCuNFgh|ryP Ml\SNVk2QDR{Mke=
UCH-1  MV\GeY5kfGmxbjDBd5NigQ>? MoXJNE02KM7:TR?= MU\pcohq[mm2czD0bIUheGixc4Doc5J6dGG2aX;uJI9nKGKxdHigRWtVKGGwZDDtWG9TKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3jNdlE6PTJ6NESx
UCH-1  MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4iyeFAvODFvMUCg{txO MoLnOkBl NGfxT4dqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHTvd4Uh\GWyZX7k[Y51dHl? M1jHbVE6PTJ6NESx
UCH-1  MVTBdI9xfG:|aYOgRZN{[Xl? NY\hSWliOC5zLUGwJO69VQ>? MVKyOEBp NUj3OIIzTE2VTx?= NXHVemU1cW6mdXPld{BieG:ydH;zbZM> NX;yeHI3OTl3Mki0OFE>

... Click to View More Cell Line Experimental Data

In vivo試験 When tumors reach 50-100 mm3, animals are randomized and treated with vehicle or PI-103. PI-103 exhibits significant activity, decreasing average tumor size by 4-fold after 18 days. [2] Mice treated with PI-103 have no obvious signs of toxicity premorbidly (based on body weight, food and water intake, activity, and general exam) or at necropsy. Treated tumors display decreased levels of phosphorylated Akt and S6, consistent with blockade of p110α and mTOR. PI-103 treatment is cytostatic to glioma xenografts. [2]
臨床試験
特集 The first potent, synthetic mTOR inhibitor.

プロトコル (参考用のみ)

キナーゼアッセイ: [3]

Enzyme Assays Phosphatidylinositide 3-kinase inhibitory activity was determined using a scintillation proximity assay in the presence of 1 μmol/L ATP. Inhibition of mTOR protein kinase was determined using a TR-FRET-based LanthaScreen method from Invitrogen. Compounds were assayed at a maximum concentration of 10 μmol/L in the presence of 1 μmol/L ATP, and IC50 values were determined using GraphPad Prism software.

細胞アッセイ: [2]

細胞株 U87MG cells
濃度 0.5 μM
反応時間 24 hours
実験の流れ U87MG cells are treated with PI-103 for 24 hours. Cell death is quantified by colorimetric determination of LDH activity using a cytotoxicity detection kit. Percentage of cell death (mean of three 12-well plates per experimental point) is calculated [(experimental value- low control)/(high control -low control) × 100], where the low-control cells are DMSO treated and high-control cells are Triton treated (1% Triton X-100, 30 min, 37 °

動物実験: [2]

動物モデル 6- to 12-week-old Balbc nu/nu mice bearing U87MG:ΔEGFR cells
製剤 50% DMSO
投薬量 5 mg/kg
投与方法 Administered via i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

参考

化学情報

Download PI-103 SDF
分子量 348.36
化学式

C19H16N4O3

CAS No. 371935-74-9
保管 2年-20℃
6月-80℃in solvent
別名 N/A
溶解度 (25°C) * In vitro DMSO 24 mg/mL (68.89 mM)
<1 mg/mL (<1 mM)
エタノール <1 mg/mL (<1 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
化学名 Phenol, 3-[4-(4-morpholinyl)pyrido[3',2':4,5]furo[3,2-d]pyrimidin-2-yl]-

カスタマーフィードバック (4)


Click to enlarge
Rating
Source Mol Carcinog, 2012, 52, 667-75 . PI-103 purchased from Selleck
Method Western blot
Cell Lines MCF7 cells
Concentrations 0-1 μM
Incubation Time 24 h
Results In BRCA1-KD MCF7 cells, treatment of PI-103, a PI3K/mTOR inhibitor, abolished phosphorylation of AKT and its substrate GSK3b, in a dose dependent manner (Figure A). Treatment of PI-103 reduced the phosphorylation of AKT in all BRCA1 mutant breast cancer cells tested (Figure B). Phosphorylations of downstream targets of AKT, such as phospho-GSK3b (S9) and phospho-BAD(S112) were also reduced by PI-103 treatment. Phosphorylation of mTOR at S2448, which is also known to be phosphorylated by AKT, was also reduced by PI-103 resulting in reduced phosphorylation of S6 ribosomal protein at S235/236 (Figure B). The effect of PI-103 was much more potent than LY294002 in MDA-MB-436 cells (Figure B)

Click to enlarge
Rating
Source Mol Carcinog, 2012, ahead of print. PI-103 purchased from Selleck
Method MTT assay
Cell Lines MCF7 cells
Concentrations 0.01-1 μM
Incubation Time 48 h
Results Knockdown of BRCA1 can sensitize the MCF7 cells to Perifosine in a dose-dependent manner (Figure A). BRCA1-KD also sensitizes the MCF7 cells to dual PI3K/mTOR inhibitors, such as PI-103 or BEZ235 (Figure B, D). Another inhibitor, PIK-75 which specifically inhibits PI3Ka and PI3Kg, but not mTOR, also showed similar effects on proliferation of BRCA1-KD MCF7 cells (Figure C).

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. PI-103 purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-1 nM
Incubation Time 24 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in Breast cancer cells.

Click to enlarge
Rating
Source Saraswati Sukumar of Johns Hopkins University School of Medicine, PI-103 purchased from Selleck
Method Western blot
Cell Lines T47D cells
Concentrations
Incubation Time 1 h
Results PI-103 treatment resulted in a reduction of Akt phosphorylation in T47D cells.

文献中の引用 (21)

技術サポート&よくある質問(FAQ)

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)

他の質問がある場合は、お気軽くお問合せください。

* 必須

Related PI3K 阻害剤

  • GDC-0032

    GDC-0032 is a potent, next-generation PI3K inhibitor targeting PI3K alpha.

    Features:A beta isoform-sparing PI3K inhibitor.

  • Pilaralisib (XL147)

    Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.

  • GNE-317

    GNE-317 is a potent, brain-penetrant PI3K inhibitor.

  • PI-3065

    PI-3065 is a selective p110δ inhibitor with IC50 of 15 nM, >70-fold selectivity over other PI3K family members.

  • LY294002

    LY294002は、p110α、p110δとp110βのPI3K阻害剤で、IC50 がそれぞれ 0.5 μM、0.57 μM、0.97 μMです。

  • 3-Methyladenine (3-MA)

    3-Methyladenine (3-MA) は選択の自噬とリン酸イノシトール3キナーゼ(キナーゼ)阻害剤、Vps34 と PI3Kγ に作用する時、 IC50 がそれぞれ 25 nM と 60 nM になる。自動食物胞の形成を妨害すること。

  • CAL-101 (Idelalisib, GS-1101)

    CAL-101 (Idelalisib, GS-1101)は、2.5nMのIC50によるp110δの選択的なPI3KクラスI阻害剤です。

  • Wortmannin

    ワートマニンはミオシン軽鎖キナーゼ(MLCK)のマルチターゲットの阻害剤、IC50がぞれぞれ0.17μMと3nMになる。自動食物胞の形成を妨害すること。

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • BKM120 (NVP-BKM120, Buparlisib)

    BKM120 (NVP-BKM120, Buparlisib)は、p110α、p110β、p110δとp110γの選択的なPI3K阻害剤で、IC50 がそれぞれ 52-99 nM、166 nM、 116 nM、 262 nMです。

最近チェックしたアイテム

Tags: PI-103を買う | PI-103供給者 | PI-103を購入する | PI-103費用 | PI-103生産者 | オーダーPI-103 | PI-103代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
お問い合わせ